TY - JOUR
T1 - Prognostic Value of Melanoma-Associated Antigen-A (MAGE-A) Gene Expression in Various Human Cancers
T2 - A Systematic Review and Meta-analysis of 7428 Patients and 44 Studies
AU - Poojary, Manish
AU - Jishnu, Padacherri Vethil
AU - Kabekkodu, Shama Prasada
N1 - Funding Information:
The authors acknowledge the infrastructure support from TIFAC CORE in Pharmacogenomics, Government of India; DST-FIST, Government of India for infrastructure support. The funding source had no involvement in the conduct of the research and/or preparation of this article. We would also like to thank Pradyumna Jayaram for providing suggestions.
Funding Information:
Open access funding provided by Manipal Academy of Higher Education, Manipal. The authors acknowledge the infrastructure support from TIFAC CORE in Pharmacogenomics, Government of India; DST-FIST, Government of India for infrastructure support. The funding source had no involvement in the conduct of the research and/or preparation of this article. We would also like to thank Pradyumna Jayaram for providing suggestions.
Publisher Copyright:
© 2020, The Author(s).
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Background: Members of the melanoma-associated antigen-A (MAGE-A) subfamily are overexpressed in many cancers and can drive cancer progression, metastasis, and therapeutic recurrence. Objective: This study is the first comprehensive meta-analysis evaluating the prognostic utility of MAGE-A members in different cancers. Methods: A systematic literature search was conducted in PubMed, Google Scholar, Science Direct, and Web of Science. The pooled hazard ratios with 95% confidence intervals were estimated to evaluate the prognostic significance of MAGE-A expression in various cancers. Results: In total, 44 eligible studies consisting of 7428 patients from 11 countries were analysed. Univariate and multivariate analysis for overall survival, progression-free survival, and disease-free survival showed a significant association between high MAGE-A expression and various cancers (P < 0.00001). Additionally, subgroup analysis demonstrated that high MAGE-A expression was significantly associated with poor prognosis for lung, gastrointestinal, breast, and ovarian cancer in both univariate and multivariate analysis for overall survival. Conclusion: Overexpression of MAGE-A subfamily members is linked to poor prognosis in multiple cancers. Therefore, it could serve as a potential prognostic marker of poor prognosis in cancers.
AB - Background: Members of the melanoma-associated antigen-A (MAGE-A) subfamily are overexpressed in many cancers and can drive cancer progression, metastasis, and therapeutic recurrence. Objective: This study is the first comprehensive meta-analysis evaluating the prognostic utility of MAGE-A members in different cancers. Methods: A systematic literature search was conducted in PubMed, Google Scholar, Science Direct, and Web of Science. The pooled hazard ratios with 95% confidence intervals were estimated to evaluate the prognostic significance of MAGE-A expression in various cancers. Results: In total, 44 eligible studies consisting of 7428 patients from 11 countries were analysed. Univariate and multivariate analysis for overall survival, progression-free survival, and disease-free survival showed a significant association between high MAGE-A expression and various cancers (P < 0.00001). Additionally, subgroup analysis demonstrated that high MAGE-A expression was significantly associated with poor prognosis for lung, gastrointestinal, breast, and ovarian cancer in both univariate and multivariate analysis for overall survival. Conclusion: Overexpression of MAGE-A subfamily members is linked to poor prognosis in multiple cancers. Therefore, it could serve as a potential prognostic marker of poor prognosis in cancers.
UR - http://www.scopus.com/inward/record.url?scp=85086580293&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086580293&partnerID=8YFLogxK
U2 - 10.1007/s40291-020-00476-5
DO - 10.1007/s40291-020-00476-5
M3 - Review article
AN - SCOPUS:85086580293
SN - 1177-1062
VL - 24
SP - 537
EP - 555
JO - Molecular Diagnosis and Therapy
JF - Molecular Diagnosis and Therapy
IS - 5
ER -
